Updated on 14 August 2013
The companies will initially place SomaLogic's SOMAscan proteomic assay, which employs custom Agilent microarrays in its workflow, in select academic and contract research centers.
Singapore: Agilent Technologies and US-based SomaLogic have entered into an agreement to expand access to SomaLogic's unbiased protein biomarker discovery platform.
The companies will initially place SomaLogic's SOMAscan proteomic assay, which employs custom Agilent microarrays in its workflow, in select academic and contract research centers. Although the SOMAscan assay is already available to researchers directly from SomaLogic as a service, this planned roll-out is aimed at meeting the rapidly growing demand for access to SomaLogic's highly multiplexed, cost-effective proteomic analyses.
"This agreement will greatly enhance our current microarray offerings by expanding them into the rapidly growing proteomics market," said Mr Jacob Thaysen, vice president and general manager of Agilent's Genomics Solutions Division. "SomaLogic's cutting-edge proteomic technology makes them an ideal partner for us to increase our presence in this growing market," he added.
"Agilent's custom microarrays have been a critical element in our development of the SOMAscan assay over the past several years," said Dr Larry Gold, chairman and CEO of SomaLogic. "We are delighted that our partnership is expanding to make the technology even more accessible to researchers everywhere," he added.